Table 3.
Select characteristics of participants who did not achieve sustained virological response
| Age, years | Sex at birth (M/F) | Current substance use at entry (Y/N) | Compensated Cirrhosis based on FIB-4/CTP (Y/N) | HIV co-infection (Y/N) | Self-reported time to completion of SOF–VEL, days | Self-reported adherence at week 24/SVR visit | HCV genotype at entry | HCV RNA at entry, log10 IU/mL | HCV RNA at week 24/SVR assessment, log10 IU/mL | Adverse event (Y/N) | Unplanned visit (Y/N) | Lost medication/premature discontinuation (Y/N) | Lost to follow-up (Y/N) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brazil | 38 | M | N | N | Y | 84 | 100% | 1a | 5·6 | 5·5 | N | N | N | N |
| Brazil | 66 | M | Y | N | N | 84 | 100% | 3a | 6·0 | 5·6 | N | N | N | N |
| Brazil | 59 | F | N | Y | N | 85 | 100% | 3a | 5·5 | 6·1 | N | N | N | N |
| Thailand | 27 | M | N | N | Y | 83 | 100% | 1a | 6·4 | 6·7 | N | N | N | N |
| Thailand | 47 | M | N | N | Y | 84 | 100% | 3b | 6·3 | 6·5 | N | N | N | N |
| Thailand | 25 | M | N | N | Y | 84 | 100% | 1a | 5·9 | 5·4 | N | N | N | N |
| Thailand | 51 | M | N | Y | Y | 84 | 100% | 3a | 6·5 | 5·8 | N | N | N | N |
| Thailand | 59 | M | N | Y | N | 85 | 100% | 3b | 6·5 | 4·1 | Y | N | N | N |
| Thailand | 33 | M | N | N | Y | 88 | 100% | 1a | 6·8 | 7·1 | Y | N | N | N |
| Thailand | 20 | F | N | N | N | 157 | 50–74% | 3b | 5·8 | 3·3 | N | N | N | N |
| USA | 24 | F | N | N | N | 6 | <50% | 3a | 4·1 | 5·5 | N | N | Y | N |
| USA | 46 | M | N | N | N | 85 | 100% | 1a | 6·5 | 6·7 | N | N | N | N |
| USA | 62 | M | N | Y | N | 85 | 100% | 1a | 6·1 | 6·5 | N | N | N | N |
| USA | 60 | M | N | N | N | 85 | 100% | 1a | 5·5 | 4·6 | N | N | N | N |
| USA | 58 | M | Y | N | N | 87 | 90–99% | 1a | 6·2 | 4·7 | N | N | N | N |
| USA | 51 | M | N | N | Y | 95 | 90–99% | 1a | 6·2 | 6·3 | N | N | N | N |
| USA | 34 | M | N | N | Y | 110 | 75–89% | 1b | 5·8 | 5·4 | N | N | N | N |
| USA | 25 | F | N | N | Y | .. | .. | 1a | 5·3 | NA | N | N | .. | Y |
| USA | 55 | M | Y | N | N | .. | .. | 1a | 5·5 | NA | N | N | .. | Y |
| USA | 59 | F | N | N | N | 51 | <50% | 1b | 6·4 | NA | Y | Y | Y | Y |
Two participants were lost to follow-up post-entry with no follow-up information beyond baseline. CTP=Child-Turcotte-Pugh. M=male. F=female. SOF–VEL=sofosbuvir–velpatasvir. Y=yes. N=no. NA=sample not available within SVR window.